| Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant J Lopez Bernal, N Andrews, C Gower, E Gallagher, R Simmons, ... New England Journal of Medicine 385 (7), 585-594, 2021 | 3256 | 2021 |
| Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard, E Gallagher, ... New England Journal of Medicine 386 (16), 1532-1546, 2022 | 2160 | 2022 |
| Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative … JL Bernal, N Andrews, C Gower, C Robertson, J Stowe, E Tessier, ... bmj 373, 2021 | 1298 | 2021 |
| Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ... The lancet 399 (10332), 1303-1312, 2022 | 1204 | 2022 |
| Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression DR Feikin, MM Higdon, LJ Abu-Raddad, N Andrews, R Araos, Y Goldberg, ... The lancet 399 (10328), 924-944, 2022 | 1140 | 2022 |
| Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study E Miller, K Hoschler, P Hardelid, E Stanford, N Andrews, M Zambon The Lancet 375 (9720), 1100-1108, 2010 | 880 | 2010 |
| Effectiveness of maternal pertussis vaccination in England: an observational study G Amirthalingam, N Andrews, H Campbell, S Ribeiro, E Kara, K Donegan, ... The Lancet 384 (9953), 1521-1528, 2014 | 863 | 2014 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 802 | 2021 |
| Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study E Miller, NJ Andrews, PA Waight, MPE Slack, RC George The Lancet infectious diseases 11 (10), 760-768, 2011 | 762 | 2011 |
| Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction CL Trotter, NJ Andrews, EB Kaczmarski, E Miller, ME Ramsay The Lancet 364 (9431), 365-367, 2004 | 751 | 2004 |
| Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre … APS Munro, L Janani, V Cornelius, PK Aley, G Babbage, D Baxter, M Bula, ... The Lancet 398 (10318), 2258-2276, 2021 | 719 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 707 | 2021 |
| Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study S de Lusignan, J Dorward, A Correa, N Jones, O Akinyemi, ... The Lancet Infectious Diseases 20 (9), 1034-1042, 2020 | 698 | 2020 |
| Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study PA Waight, NJ Andrews, SN Ladhani, CL Sheppard, MPE Slack, E Miller The Lancet infectious diseases 15 (5), 535-543, 2015 | 688 | 2015 |
| Population‐based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 WA Knowles, P Pipkin, N Andrews, A Vyse, P Minor, DWG Brown, E Miller Journal of medical virology 71 (1), 115-123, 2003 | 662 | 2003 |
| Duration of protection against mild and severe disease by Covid-19 vaccines N Andrews, E Tessier, J Stowe, C Gower, F Kirsebom, R Simmons, ... New England Journal of Medicine 386 (4), 340-350, 2022 | 615 | 2022 |
| Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study NJ Andrews, PA Waight, P Burbidge, E Pearce, L Roalfe, M Zancolli, ... The Lancet infectious diseases 14 (9), 839-846, 2014 | 554 | 2014 |
| Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity MCJ Maiden, AB Ibarz-Pavón, R Urwin, SJ Gray, NJ Andrews, SC Clarke, ... The Journal of infectious diseases 197 (5), 737-743, 2008 | 537 | 2008 |
| Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study SN Ladhani, S Collins, A Djennad, CL Sheppard, R Borrow, NK Fry, ... The Lancet Infectious Diseases 18 (4), 441-451, 2018 | 534 | 2018 |
| Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis ME Ramsay, NJ Andrews, CL Trotter, EB Kaczmarski, E Miller Bmj 326 (7385), 365-366, 2003 | 534 | 2003 |
Elizabeth MillerProfessorVerified email at lshtm.ac.uk
